Skip to main content

Advertisement

SpringerLink
Log in

Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To report 6 months of results of combined treatment of intravitreal bevacizumab and triamcinolone in patients with retinal vein occlusion (RVO).

Study design/Methods

Retrospective consecutive case series. Intravitreal bevacizumab (1.25 mg) combined with intravitreal triamcinolone (2 mg) was injected to 16 patients with RVO: eight with branch retinal vein occlusion (BRVO) and eight with central retinal vein occlusion (CRVO). Patient’s charts were reviewed for age, sex, previous ocular interventions, duration of follow-up, number of intraocular injections, intraocular pressure (IOP) and central macular thickness measured by optical coherence tomography (OCT). We included only patients that completed 6 months of follow-up.

Results

Mean age and number of injections were 72.9 ± 11.99 years, and 2 ± 0.81 respectively. In eight patients with CRVO, initial visual acuity was logMAR 1.09 ± 0.67 and mean visual acuity at 1, 3 and 6 months was logMAR 0.98 ± 0.55 (p = 0.59), 1.33 ± 1.05 (p = 0.4) and 1.4 ± 1.2 (p = 0.34) respectively. In eight patients with BRVO, initial visual acuity was logMAR 1.025 ± 0.58 and mean visual acuity at 1, 3, and 6 months was 0.56 ± 0.21 (p = 0.05), 0.61 ± 0.17 (p = 0.03) and 0.66 ± 0.34 (p = 0.12) respectively. Mean initial central macular thickness for the whole group was 527 ± 182 μm and mean central macular thickness at 6 months was 379 ± 156 μm (p < 0.001).

Conclusion

This study suggests that combined treatment with intravitreal bevacizumab and intravitreal triamcinolone improves structural outcome in patients with retinal vein occlusion. In our study, the combination of triamcinolone acetonide and bevacizumab offered no advantage over previously published results with intravitreal bevacizumab injections alone for improving vision at 6 months

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bearelly S, Fekrat S (2004) Controversy in the management of retinal venous occlusive disease. Int Ophthalmol Clin 44(4):85–102

    Article  PubMed  Google Scholar 

  2. Dithmar S, Hansen LL, Holz FG (2003) Retinal vein occlusion. Ophthalmologe 100:561–577

    Article  CAS  PubMed  Google Scholar 

  3. Clarkson JG (1994) Central vein occlusion study: photographic protocol and early natural history. Trans Am Ophthalmol Soc 92:203–213

    CAS  PubMed  Google Scholar 

  4. Rehak J, Rehak M (2008) Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33:111–131

    Article  PubMed  Google Scholar 

  5. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK (2006) Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 244:309–315

    Article  CAS  PubMed  Google Scholar 

  6. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, Martin JF, Hykin PG (2002) Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 120:1644–1650

    CAS  PubMed  Google Scholar 

  7. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JU, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR (2008) Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 16:791–799

    Article  CAS  PubMed  Google Scholar 

  8. Kaur C, Foulds WS, Ling EA (2008) Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 27(6):622–647

    Article  CAS  PubMed  Google Scholar 

  9. Tao Y, Hou J, Jiang YR, Li XX, Jonas JB (2009) Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye. Aug 21 doi:10.1038/eye.2009.220

  10. Wu WC, Cheng KC, Wu HJ (2009) Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye Feb 13. doi:10.1038/eye.2008.429

  11. Kondo M, Kondo N, Ito Y, Kachi S, Kikuchi M, Yasuma TR, Ota I, Miyake K, Terasaki H (2009) Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina Aug 10. doi:10.1097/IAE.0b013e3181aa8e20

  12. Gregori NZ, Rattan GH, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, Murray TG (2009) Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina 29(7):913–925

    Article  PubMed  Google Scholar 

  13. Fish GE (2008) Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion (an AOS thesis). Trans Am Ophthalmol Soc 106:276–300

    PubMed  Google Scholar 

  14. Ekdawi NS, Bakri SJ (2007) Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone. Eye 21:1128–1130

    Article  CAS  PubMed  Google Scholar 

  15. Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmology 98:271–282

    Google Scholar 

  16. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M, SCORE Study Research Group (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6. Arch Ophthalmol 127(9):1115–1128

    Article  PubMed  Google Scholar 

  17. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND (2009) Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina 29(4):511–515

    Article  PubMed  Google Scholar 

  18. Karacorlu M, Karacorlu SA, Ozdemir H, Senturk F (2007) Intravitreal triamcinolone acetonide for treatment of serous macular detachment in central retinal vein occlusion. Retina 27(8):1026–1030

    Article  PubMed  Google Scholar 

  19. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW Jr, Lee JE, Mavrofrides EC, Smiddy WE, Murray TG, Berrocal AM, Scott IU, Gregori G (2006) One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 26(8):889–895

    Article  PubMed  Google Scholar 

  20. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF (2005) Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 15(6):751–758

    CAS  PubMed  Google Scholar 

  21. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF (2005) Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 19(1):65–71

    Article  CAS  PubMed  Google Scholar 

  22. Roth DB, Cukras C, Radhakrishnan R, Feuer WJ, Yarian DL, Green SN, Wheatley HM, Prenner J (2008) Intravitreal triamcinolone acetonide injections in the treatment of retinal vein occlusions. Ophthalmic Surg Lasers Imaging 39(6):446–454

    Article  PubMed  Google Scholar 

  23. Williamson TH, O’Donnell A (2005) Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol 139(5):860–866

    Article  CAS  PubMed  Google Scholar 

  24. Bashshur ZF, Ma’luf RN, Allam S, Jurdi FA, Haddad RS, Noureddin BN (2004) Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 122(8):1137–1140

    Article  CAS  PubMed  Google Scholar 

  25. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH, SCORE Study Research Group (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. Arch Ophthalmol. 127(9):1101–1114

    Article  PubMed  Google Scholar 

  26. Wang L, Song H (2009) Effects of repeated injection of intravitreal triamcinolone on macular oedema in central retinal vein occlusion. Acta Ophthalmol 87(3):285–289

    Article  PubMed  Google Scholar 

  27. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26(3):279–284

    Article  PubMed  Google Scholar 

  28. Hsu J, Kaiser RS, Sivalingam A, Abraham P, Fineman MS, Samuel MA, Vander JF, Regillo CD, Ho AC (2007) Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina 27(8):1013–1019

    Article  PubMed  Google Scholar 

  29. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27(4):419–425

    Article  PubMed  Google Scholar 

  30. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92(4):518–522

    Article  CAS  PubMed  Google Scholar 

  31. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, Schmidt-Erfurth UM (2009) Intravitreal bevacizumab (Avastin(R)) for macular edema secondary to retinal vein occlusion—twelve-month results of a prospective clinical trial. Br J Ophthalmol 93(4):452–456

    Article  CAS  PubMed  Google Scholar 

  32. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P (2009) One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247(1):27–33

    Article  CAS  PubMed  Google Scholar 

  33. Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Jennifer K. Sun, of the Diabetic Retinopathy Clinical Research Network (2008) Retinal thickness on stratus optical coherence Tomography™ in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol 145(5):894–901

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, IN, 46202, USA

    Rita Ehrlich, Adam M. Moss & Alon Harris

  2. Retina Service, Midwest Eye Institute, Attending Physician and Surgeon, Methodist Hospital, Indianapolis, IN, USA

    Thomas A. Ciulla

Authors
  1. Rita Ehrlich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas A. Ciulla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adam M. Moss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alon Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rita Ehrlich.

Additional information

The authors have no financial interest relevant to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ehrlich, R., Ciulla, T.A., Moss, A.M. et al. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol 248, 375–380 (2010). https://doi.org/10.1007/s00417-009-1211-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-009-1211-6

Keywords

Search

Navigation